Phaseline

Targets › CD46

CD46 (Membrane cofactor protein): drug programs, companies and trials

5 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.

Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. (UniProt, P15529)

Open in Phaseline: the race on CD46, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kyntra BioFG-3246
anti-CD46 antibody-drug conjugate
CD46Phase 2Metastatic Castration-Resistant Prostate CancerMar 2028
Robert Flavell, MD, PhDZirconium Zr 89-DFO-YS5
anti-CD46 radiopharmaceutical tracer (Zr-89 labeled)
CD46Phase 1Multiple MyelomaJan 2027
Robert Flavell, MD, PhD89Zr-DFO-YS5
anti-CD46 antibody labeled with zirconium-89 for PET imaging
CD46Phase 1Prostate CancerJul 2027
Rahul AggarwalFOR46
anti-CD46 antibody-drug conjugate
CD46Phase 1Metastatic Castration-resistant Prostate CancerJul 2027
Robert Flavell, MD, PhDYS5 antibody
anti-CD46 monoclonal antibody
CD46Phase 1Prostate CancerJul 2027

Conditions

Prostate Cancer (2) Multiple Myeloma (1) Metastatic Castration-resistant Prostate Cancer (1) Metastatic Castration-Resistant Prostate Cancer (1)

Modalities

mixed (2), small molecule (2), protein or peptide (1)

Companies

Robert Flavell, MD, PhD (3) Rahul Aggarwal (1) Kyntra Bio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.